Recent findings on the mechanism of action of morphine: Implications for the development of new analgesics

CNS Drugs

Volumn 10, Issue 1, 1998, Pages 1-10

  Valverde, Olga ^a   Maldonado, Rafael ^a   Kieffer, Brigitte L ^b  

^a Laboratoire de Pharmacochimie   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; BETA ENDORPHIN; DELTA OPIATE RECEPTOR; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLORNITHYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; DIPRENORPHINE; DYNORPHIN A; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; KAPPA OPIATE RECEPTOR; LEUCINE ENKEPHALIN; LEUCINE ENKEPHALIN[2 DEXTRO SERINE 6 THREONINE]; METENKEPHALIN; MORPHINE; MU OPIATE RECEPTOR; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; NALOXONE; NALTRINDOLE; NARCOTIC ANALGESIC AGENT; NEW DRUG; NORBINALTORPHIMINE; OPIATE PEPTIDE; OPIATE RECEPTOR;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENE TARGETING; HOT PLATE TEST; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRASPINAL DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; LIGAND BINDING; MORPHINE ADDICTION; MOTIVATION; MOUSE MUTANT; NONHUMAN; PRIORITY JOURNAL; REWARD; SUBCUTANEOUS DRUG ADMINISTRATION; TAIL FLICK TEST;

EID: 0031843060     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199810010-00001     Document Type: Article

References (58)

1. Simon EJ. Opioid receptors and endogenous opioid peptides. Med Res Rev 1991; 11: 357-74
2. Hughes J, Smith TW, Kosterlitz HW. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 1975; 258: 577-9
3. Akil H, Watson SJ, Young E, et al. Endogenous opioids: biology and function. Annu Rev Neurosci 1984; 7: 223-55
4. Evans CJ, Keith E, Morrison H, et al. Cloning of a delta receptor by functional expression. Science 1992; 258: 1952-5
5. Kieffer BL, Befort K, Gaveriaux-Ruff C, et al. The delta opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA 1992; 89: 12048-52
6. Kieffer BL. Recent advances in molecular recognition and signal transduction of active peptides: receptor for opioid peptides. Cell Mol Neurobiol 1995; 15: 615-35
7. Kieffer BL. Molecular aspects of opioid receptors. In: Dickenson A, Besson JM, editors. Pain: handbook of experimental pharmacology. Berlin: Springer-Verlag, 1997: 281-303
8. Goodman RR, Adler BA, Pasternak GW. Regional distribution of opioid receptors. In: Pasternak GW, editor. The opiate receptors. Clifton (NJ): The Human Press, 1988: 197-230
9. Mansour A, Fox CA, Akil H, et al. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 1995; 18: 22-9
10. Matthes H, Maldonado R, Simonin F, et al. Abolition of morphine-induced analgesia, reward and physical dependence in mice lacking the μ-opioid receptor gene. Nature 1996; 383: 819-23
11. Ward SJ, Takemori AE. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice. J Pharmacol Exp Ther 1983; 224: 525-30
12. Lipp J. Possible mechanisms of morphine analgesia. Clin Neuropharmacol 1991; 14: 131-47
13. Yaksh TL, Rudy TA. Studies on the direct spinal action of narcotics in the production of analgesia in the rat. J Pharmacol Exp Ther 1977; 202: 411-28
14. Przewlocki R, Stala L, Greczek M, et al. Analgesic effects of mu-, delta- and kappa-opiate agonists and in particular, dynorphin at the spinal level. Life Sci 1983; 33: 649-52
15. Schumauss C, Yaksh TL. In vivo studies on spinal opiate receptor systems mediating antinociception. II. Pharmacological profiles suggesting a differential association of mu, delta and kappa receptors with visceral chemical and cutaneous thermal stimuli in the rat. J Pharmacol Exp Ther 1984; 228: 1-12
16. Porreca F, Mosberg HI, Hurst R, et al. Role of mu, delta and kappa opioid receptors in the spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. J Pharmacol Exp Ther 1984; 230: 341-8
17. Millan MJ. Kappa-opioid receptor-mediated antinociception in the rat. I. Comparative actions of mu- and kappa-opioids against noxious thermal, pressure and electrical stimuli. J Pharmacol Exp Ther 1989; 251: 334-51
18. Stevens CW, Yaksh TL. Magnitude of opioid dependence after continuous intrathecal infusion of mu- and delta-selective opioids in the rat. Eur J Pharmacol 1989; 166: 467-72
19. 5]enkephalin in the rat. J Pharmacol Exp Ther 1991; 259: 725-31
20. Calcagnetti DJ, Holtzman SG. Delta opioid antagonist, naltrindole, selectively blocks analgesia induced by DPDPE but not DAGO or morphine. Pharmacol Biochem Behav 1991; 38: 185-90
21. Roering SC, Fujimoto JM. Multiplicative interaction between intrathecally and intracerebroventricularly administered mu opioid agonists but limited interactions between delta and kappa agonists for antinociception in mice. J Pharmacol Exp Ther 1989; 249: 762-8
22. Sofuoglu M, Portoghese PS, Takemori AE. Differential antagonism of DSLET and DPDPE by novel delta opioid receptor antagonists. Eur J Pharmacol 1990; 183: 2322-32
23. Traynor JR, Hunter JD, Rodriguez RE, et al. Delta-opioid receptor binding sites in rodent spinal cord. Br J Pharmacol 1990; 100: 319-23
24. Dickenson AH, Sullivan AF, Knox RJ, et al. Opioid receptor sub-types in the rat spinal cord: electrophysiological studies with mu and delta opioid receptor agonists in the control of nociception. Brain Res 1987; 413: 36-44
25. Dickenson AH. Recent advances in the physiology and pharmacology of pain: plasticity and its implications for clinical analgesia. J Psychopharmacol 1991; 5: 342-51
26. Satoh M, Kubota A, Iwama T, et al. Comparison of analgesic potencies of mu, delta and kappa agonists locally applied to various CNS regions relevant to analgesia in rats. Life Sci 1983; 33: 689-92
27. Millan MJ, Czlonkowski A, Lipkowski A, et al. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action. J Pharmacol Exp Ther 1989; 251: 342-50
28. Ossipov MH, Kovelowski CJ, Nichols ML, et al. Characterization of supraspinal antinociceptive actions of opioid delta agonists in the rat. Pain 1995; 62: 287-93
29. 1-opiate receptors in supraspinal opiate analgesia: a microinjection study. Brain Res 1988; 447: 25-34
30. Baamonde A, Daugé V, Gacel G, et al. Systemic administration of (Tyr-D-Ser(O-Tert-Butyl)-Gly-Phe-Leu-Thr(O-Tert-Butyl), a highly selective delta opioid agonist, induces mu receptor-mediated analgesia in mice. J Pharmacol Exp Ther 1991; 257: 767-73
31. Heyman JS, Jiang Q, Rothman RB, et al. Modulation of mu-mediated antinociception by delta agonists in the mouse: pharmacological characterisation with antagonists. Eur J Pharmacol 1989; 169: 43-52
32. Erspamer V, Melchiorri P, Falconieri-Erspamer G, et al. Deltorphins: a family of naturally occurring peptides with high affinity and selectivity for delta opioid binding sites. Proc Natl Acad Sci USA 1989; 86: 5188-92
33. 2]deltorphin II. a highly selective delta agonist in vivo. Life Sci 1990; 40: PL43-7
34. Miaskowski C, Taiwo YO, Levine JD. Contribution of supraspinal mu- and delta-opioid receptors to antinociception in the rat. Eur J Pharmacol 1991; 205: 247-52
35. Daugé V, Petit F, Rossignol P, et al. Use of mu and delta opioid peptides of various selectivity gives further evidence of specific involvement of mu opioid receptors in supraspinal analgesia (taif-flick test). Pain 1987; 14: 171-8
36. 2-agonist antinociception. Neuroreport 1994; 5: 1049-52
37. Kest B, Lee CE, McLemore GL, et al. An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice. Brain Res Bull 1996; 39: 185-8
38. 5 enkephalin in the mouse. J Pharmacol Exp Ther 1987; 241: 393-400
39. Zadina JE, Hackler L, Ge LJ, et al. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 1997; 386: 499-501
40. Mucha RF, Van der Kooy D, O'Shaughnessy M, et al. Drug reinforcement studied with place and taste preference conditioning. Psychopharmacology 1982; 86: 274-80
41. Valverde O, Fournié-Zaluski MC, Roques BP, et al. CCK-B receptor antagonist, PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats. Psychopharmacology 1996; 123: 119-26
42. Funada M, Narita M, Suzuki T, et al. Effect of pretreatment with pertussis toxin on the development of physical dependence on morphine. Naunyn Schmiedebergs Arch Pharmacol 1993; 348: 88-95
43. Shippenberg TS, Bals-Kubik R, Herz A, et al. Motivational properties of opioids: evidence that an activation of delta-receptors mediates reinforcement processes. Brain Res 1987; 436: 234-9
44. Bals-Kubik R, Ableitner A, Herz A, et al. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther 1993; 264: 489-95
45. Phillips AG, LePiane FG. Reinforcing effects of morphine microinjections into ventral tegmental area. Pharmacol Biochem Behav 1980; 12: 965-8
46. Suzuki T, Tsuji M, Mori T, et al. Involvement of dopamine-dependent and -independent mechanisms in the rewarding effects mediated by delta opioid receptor subtypes in mice. Brain Res 1997; 744: 327-34
47. Pfeiffer A, Brantl V, Herz A, et al. Psychotomimesis mediated by kappa-opioid receptors. Science 1986; 233; 774-6
48. Cowan A, Zhu XZ, Mosberg HI, et al. Direct dependence studies in rats with agents selective for different types of opioid receptor. J Pharmacol Exp Ther 1988; 246: 950-5
49. Young GA, Khazan N. Comparison of abstinence syndrome following chronic administration of mu and kappa opioid agonists in the rat. Pharmacol Biochem Behav 1985; 23; 457-60
50. Maldonado R, Féger J, Fournié-Zaluski MC, et al. Differences in physical dependence induced by selective mu or delta opioid agonists and by exogenous enkephalins protected by peptidase inhibitors. Brain Res 1990; 520: 247-54
51. Aceto MD, Harris LS, Dewey WL, et al. Department studies of new compounds in the rhesus monkey. NIDA Res Monogr 1979; 27: 337-52
52. Maldonado R, Negus S, Koob GF. Precipitation of morphine withdrawal syndrome in rats in administration of mu-, delta-and kappa-selective opioid antagonists. Neuropharmacology 1992; 31: 1231-41
53. Suzuki T, Fukagawa Y, Misawa M, et al. 'Paradoxical' analgesia and aggravated morphine dependence induced by opioid antagonists. Life Sci 1990; 47: 515-21
54. Fukagawa Y, Katz JL, Suzuki T. Effects of a selective kappa-opioid agonist, U-50,488H, on morphine dependence in rats. Eur J Pharmacol 1989; 170: 47-51
55. Miyamoto Y, Portoghese PS, Takemori AE. Involvement of delta2 opioid receptors in the development of morphine dependence in mice. J Pharmacol Exp Ther 1993; 264: 1141-5
56. Funada M, Schutz CG, Shippenberg TS. Role of delta-opioid receptors in mediating the aversive stimulus effects of morphine withdrawal in the rat. Eur J Pharmacol 1996; 300: 17-24
57. Keith DE, Murray SR, Zaki PA, et al. Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 1996; 271: 19021-4
58. Rothman RB, Holaday JW, Porreca F. Allosteric coupling among opioid receptors: evidence for an opioid receptor complex. In: Herz A, editor. Opioids I. Handbook of experimental pharmacology. Berlin: Springer-Verlag, 1993: 217-37